{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06024746",
            "orgStudyIdInfo": {
                "id": "202303CPC"
            },
            "organization": {
                "fullName": "Colorado Prevention Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)",
            "officialTitle": "Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)",
            "acronym": "CONFIRMATION",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "a-study-to-determine-the-efficacy-and-safety-of-finerenone-and-in-combination-in-hospitalized-patients-with-heart-failure-confirmation-hf"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-22",
            "studyFirstSubmitQcDate": "2023-09-05",
            "studyFirstPostDateStruct": {
                "date": "2023-09-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Colorado Prevention Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Saint Luke's Hospital of Kansas City",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Bayer",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Combination therapy with finerenone with empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.",
            "detailedDescription": "This is an international, randomized, controlled, open-label, trial of an early, intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor (SGLT2i) compared with usual care in patients hospitalized with heart failure (HF)."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Failure"
            ],
            "keywords": [
                "Heart Failure",
                "Hospitalized"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 1500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Finerenone plus empagliflozin",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Finerenone",
                        "Drug: Empagliflozin"
                    ]
                },
                {
                    "label": "Usual care",
                    "type": "NO_INTERVENTION",
                    "description": "Usual care management"
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Finerenone",
                    "description": "Oral finerenone.",
                    "armGroupLabels": [
                        "Finerenone plus empagliflozin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Empagliflozin",
                    "description": "Oral empagliflozin.",
                    "armGroupLabels": [
                        "Finerenone plus empagliflozin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Clinical benefit",
                    "description": "Hierarchical composite of the following assessed by the win-ratio:\n\n* Time to death from any cause\n* Number of HF events\n* Time to first HF event\n* Difference of 5 points or greater on the Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS)",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Number of serious adverse events (AEs).",
                    "description": "- Serious AEs (excluding efficacy endpoints).",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Number of adverse events leading to discontinuation of study drug.",
                    "description": "- AEs leading to discontinuation of finerenone or empagliflozin.",
                    "timeFrame": "6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of deaths from any cause and total HF events.",
                    "description": "- All-cause mortality and total HF events (first and recurrent).",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Change from baseline in the Total Symptom Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-TSS) at Month 6.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Number of HF events at Day 90.",
                    "description": "- Total (first and recurrent) HF events.",
                    "timeFrame": "90 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Provide electronic or written informed consent, either personally or through a legally authorized representative\n* Age \u226518 years or legal age of majority\n* Current hospitalization or recently discharged with the primary diagnosis of heart failure\n* Heart failure signs and symptoms at the time of hospital admission\n* Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) \u22651000 pg/mL or B-type natriuretic peptide (BNP) \u2265250 pg/mL according to the local lab for patients in sinus rhythm; or elevated NTproBNP \u22652000 pg/mL or BNP \u2265500 pg/mL for patients with atrial fibrillation (AF), measured during the current hospitalization or in the 72 hours prior to hospital admission\n* Fulfillment of protocol defined stabilization criteria (if randomized during hospitalization)\n* Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide, torsemide, bumetanide).\n* Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes or prior history of diabetic ketoacidosis\n* Documented prior history of severe hyperkalemia in the setting of MRA use\n* Treatment with non-steroidal mineralocorticoid receptor antagonist (MRA) or SGLT2i\n* Estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73m\u00b2 and/or serum/plasma potassium \\>5.0 mmol/L\n* Type 1 acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days\n* Prior or planned heart transplant\n* Hemodynamically significant uncorrected primary cardiac valvular disease as primary cause of heart failure\n* Cardiomyopathy due to acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction\n* Probable alternative cause of participant's heart failure symptoms\n* Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers\n* Any other condition or therapy which would make the patient unsuitable for this study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Marc Bonaca",
                    "role": "CONTACT",
                    "phone": "(303) 860-9900",
                    "email": "info@cpcmed.org"
                }
            ],
            "locations": [
                {
                    "facility": "Kansas City, MO Investigative Site",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Missouri",
                    "zip": "64111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marc Bonaca",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.09973,
                        "lon": -94.57857
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No current plan to share individual patient data with other researchers."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000570240",
                    "term": "Empagliflozin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000077203",
                    "term": "Sodium-Glucose Transporter 2 Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M258082",
                    "name": "Empagliflozin",
                    "asFound": "Continued",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}